This makes alignment of HLA-II ligands difficult, especially in HLA peptidomics data where peptides found in a sample come from multiple alleles. Accordingly, class II epitope predictions display low accuracy 5, 6 . Recent developments in HLA peptidomics [7] [8] [9] are promising to improve epitope predictions, as shown in multiple studies of HLA-I molecules [10] [11] [12] [13] [14] 16, 17 , MoDec is a fully probabilistic framework that allows motifs to be found everywhere on the peptide sequences and learns both the motifs as well as their respective weights and preferred binding core position offsets (Fig. 1b) . MoDec shows conceptual similarity with convolutional neural networks (each motif can be thought of as a filter) but provides direct interpretation and visualization of the results as sequence logos (Fig.   1b) . Applying MoDec to our data, we found an abundance of motifs (Suppl. Fig. 1 ). HLA-II binding motifs identified across samples with shared HLA-II alleles displayed very high similarity ( Fig. 1c and Suppl. Fig. 2 ). This demonstrates high reproducibility of our motif deconvolution approach and enabled us to unambiguously annotate the different motifs to their respective alleles. Comparison with known motifs from databases such as IEDB 18 , or predictions from NetMHCIIpan 19 showed some similarity but also some important differences (Suppl. Fig. 2 ). In particular, the motifs deconvolved from HLA-II peptidomics data tend to show clearer anchor residues and some motifs displayed a novel type of binding specificity (Suppl. Fig. 2 ).
Here, we profiled the HLA-II peptidome of 13 different cell lines or tissue samples and identified 40'864 unique HLA-II ligands. We completed these data with our recent publication 7 . Unlike previous approaches to analyze HLA-II ligands that attempted to align the peptides 16, 17 , MoDec is a fully probabilistic framework that allows motifs to be found everywhere on the peptide sequences and learns both the motifs as well as their respective weights and preferred binding core position offsets (Fig. 1b) . MoDec shows conceptual similarity with convolutional neural networks (each motif can be thought of as a filter) but provides direct interpretation and visualization of the results as sequence logos (Fig.   1b) . Applying MoDec to our data, we found an abundance of motifs (Suppl. Fig. 1 ). HLA-II binding motifs identified across samples with shared HLA-II alleles displayed very high similarity ( Fig. 1c and Suppl. Fig. 2 ). This demonstrates high reproducibility of our motif deconvolution approach and enabled us to unambiguously annotate the different motifs to their respective alleles. Comparison with known motifs from databases such as IEDB 18 , or predictions from NetMHCIIpan 19 showed some similarity but also some important differences (Suppl. Fig. 2 ). In particular, the motifs deconvolved from HLA-II peptidomics data tend to show clearer anchor residues and some motifs displayed a novel type of binding specificity (Suppl. Fig. 2 ).
The clearest and most frequent motifs that we identified correspond to HLA-DR alleles.
To further validate them, we sequentially purified first the HLA-DR molecules with anti-HLA-DR antibody and then the remaining HLA-II molecules with a pan-HLA-II antibody (42'903 and 27'692 unique peptides respectively, leading to a total of 99'265 unique peptides across all our samples, see Methods and Suppl. Data 2) . We observed that the motifs deconvolved from HLA-DR peptidomes are identical to those assigned to HLA-DR alleles from the pan-HLA-II peptidomes (Fig. 1d and Suppl. Fig. 3 ). In addition, in the HLA-DR-depleted samples, all motifs previously predicted to correspond to HLA-DP or -DQ alleles could be found, indicating that our motif deconvolution approach in pan-HLA-II peptidomes is not restricted to HLA-DR motifs and that MoDec performs well in pan-HLA-II data ( Fig. 1d and Suppl. Fig. 3 ). Compared to other motif deconvolution methods 17, 20 , MoDec shows improved resolution and is 100-10'000 times faster (Suppl. We next investigated properties of naturally presented HLA-II ligands beyond the binding specificity of HLA-II alleles. We first grouped all our HLA-II ligands and used MoDec to identify motifs occurring three amino acids upstream and downstream of the N-or C-terminus of the peptides (see Methods). Multiple motifs appeared (Suppl. Fig.   5a -b), some of which had been suggested to represent different peptide processing and cleavage pathways 21 . The specificity was in general stronger for amino acids inside the peptide than those in flanking regions (Suppl. Fig. 5a-b) . In particular, clear enrichment was observed for proline two residues downstream of the N-terminus and upstream of the C-terminus, confirming previous observations made for a limited number of alleles 15, 21 . All alleles showed such a proline enrichment (Suppl. Fig. 5c-d) . Binding assay experiments for three HLA-DRB1 alleles demonstrate that the binding affinity is similar between peptides containing proline or alanine at the 2 nd position (Suppl. Fig. 5e ), validating the hypothesis that proline enrichment is due to the peptide processing and loading independently of the binding specificity of the HLA-II molecules. We then observed that the peptide length distribution was conserved between HLA-II alleles (Suppl. Fig. 6a ), unlike for HLA-I alleles 22 . The distribution of binding core offsets was also independent of the alleles (Suppl. Fig. 6b) , with a slight shift of the core towards the C-terminus (i.e. slightly more amino acids extend outside of the binding core on the Nterminus than the C-terminus).
We then took advantage of our deconvolved HLA-II peptidomics datasets to train a predictor of HLA-II ligands (MixMHC2pred, see Methods). This predictor combines allele-specific peptide binding motifs and allele-independent peptide N-/C-terminal motifs, peptide length and binding core offset preferences (see Methods). We first performed predictions on multiple HLA-II peptidomics datasets from independent studies (Suppl. Table 2 ) and observed improved accuracy with our predictor compared to NetMHCIIpan 19 , the state-of-the-art predictor for HLA-II ligands (Fig. 2a , Suppl. Fig. 7 ). These results also show the superiority of the full predictor combining the binding motifs, N-/C-terminal motifs, peptide length and binding core offset, compared to a predictor based only on the binding motifs or a combination of the binding motifs with any of the other allele-independent characteristics (Fig. 2a, Suppl. Fig. 7 ). To investigate whether MixMHC2pred was appropriate not only for HLA-II ligands but also for class II epitope predictions, we compiled all CD4+ T cell tetramer assays found in IEDB 18 . Receiver operating characteristic (ROC) curve analysis showed that MixMHC2pred was more accurate than NetMHCIIpan (Fig. 2b) . We further surveyed a set of several known melanoma-associated antigens and viral and bacterial proteins (Suppl . Table 3a and Methods). Top hits from MixMHC2pred and from NetMHCIIpan for tumor-associated antigens (top 30 peptides) and viral/bacterial antigens (top 30 peptides) were tested for class II immunogenicity in two melanoma patients (Suppl. The same peptides were also tested with CD4+ T cells from a healthy donor resulting in many correctly predicted epitopes and similar yield between the two predictors (Suppl. Fig. 8a ). We next took advantage of a class II immunogenic mutation (D246N in SGOL1) that was recently identified in an ovarian cancer patient by screening tumor infiltrating lymphocytes (TILs) with minigenes (see Methods and Suppl. Fig. 9 ).
To determine the actual epitope, we applied both MixMHC2pred and NetMHCIIpan on the 31-mer coded by the minigene initially used to test immunogenicity. The results indicate that here again our approach could accurately predict the actual epitope from the 31-mer (Fig. 2d , Suppl. Fig. 10 and Methods).
By combining in-depth HLA-II peptidomics data of 49 different samples together with a novel motif deconvolution approach (MoDec), we show that we can capitalize on accurate and unbiased MS profiling of HLA-II ligands for class II epitope predictions. The very high similarity between HLA-DR motifs identified in pan-HLA-II and HLA-DR peptidomes shows that all HLA-DR motifs can be accurately resolved in the pan-HLA-II samples with MoDec. This indicates that mono-allelic samples are not needed to determine HLA-DR motifs, thereby greatly reducing the amount of experimental work of future studies. Whether increased detection efficacy could be obtained by using anti-HLA-DP and anti-HLA-DQ antibodies remains to be seen and our motif deconvolution tool may prove highly valuable to analyze such data once they become available.
Although our approach may still not capture the full complexity of class II antigen presentation (e.g., differences between endocytic and phagocytic pathways 1 ), the use of MS data enabled us to incorporate N-and C-terminal motifs, as well as peptide length and binding core offset preferences, in addition to binding specificity of HLA-II alleles.
The large allele coverage (especially for HLA-DR alleles) makes our predictor suitable for a wide range of applications in infectious diseases, autoimmunity and cancer immunotherapy.
Methods
Methods and any associated references are available in the online version of the paper.
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HLA typing
Genomic DNA was extracted using DNeasy kit from Qiagen and 500 ng of gDNA were used to amplify HLA genes by PCR. High resolution 4-digit HLA typing was performed with the TruSight HLA v2 Sequencing Panel from Illumina on a MiniSeq instrument (Illumina). Sequencing data were analyzed with the Assign TruSight HLA v2.1 software (Illumina) and are provided as Suppl. Table 1 .
Generation of antibody-crosslinked beads
Anti-pan-HLA-II and anti-HLA-DR monoclonal antibodies were purified from the supernatant of HB145 (ATCC® HB-145™) and HB298 cells (ATCC® HB-298™), respectively, grown in CELLLine CL-1000 flasks (Sigma-Aldrich, St. Louis, Missouri) using Protein A-Sepharose 4B beads (Pro-A beads; Invitrogen, Carlsbad, California). Thereafter, HLA-II and HLA-DR peptides were eluted with 500 µL of 32% ACN in 0.1% TFA into a collection plate. Recovered HLA-II and HLA-DR peptides were dried using vacuum centrifugation (Concentrator plus Eppendorf) and stored at -20°C.
LC-MS/MS analyses of HLA-II peptides
Prior to MS analysis HLA-II and HLA-DR peptide samples were re-suspended in 10 
Peptide identification
We employed the MaxQuant platform 26 version 1.5.5.1 to search the peak lists against a fasta file containing the human proteome (Homo_sapiens_UP000005640_9606, the reviewed part of UniProt, with no isoforms, including 21,026 entries downloaded in 
Motif deconvolution algorithm for HLA-II peptidomics
In HLA-II peptidomics data, the HLA-II ligands are coming from different alleles, are of different lengths, and their binding core positions are a priori unknown. To account for this, and building upon the successful application of the mixture model to HLA-I peptidomics 10 , we developed a probabilistic framework able to learn multiple motifs anywhere on the peptides, as well as the weights and binding core offsets of these motifs. The log-likelihood is given by the following equation (see also Fig. 1b) :
where N is the number of peptides; W n is the similarity weight of n th peptide (see below); K is the number of motifs; S is the maximal binding core offset ( = � The optimal number of motifs (K) was first determined using the Akaike Information Criterion (AIC):
where nparams is the number of free parameters, naa is the number of different amino acids (20) and the other parameters have been defined earlier. This Akaike Information criterion is commonly used in information theory to determine the information gained from using a model with more parameters over a simpler model (the smallest AIC value the better). However, as with HLA-I peptidomics data 10 (and more generally with many clustering approaches), the optimal number of motifs is difficult to determine in a fully unsupervised way. We therefore explored additional motifs, tried further splitting specific motifs, and manually curated each dataset for consistency across samples.
Comparison between the numbers of motifs manually curated or determined by the AIC shows that in most cases the correct number of motifs would have been found with AIC and in 80% of the cases the error when using this criterion would be at most of 1 motif ( Supplementary Fig. 11 ), suggesting that AIC is a good starting point for the selection of the optimal number of motifs.
Assignment of motifs to alleles
To annotate the different motifs to their respective alleles, we used an iterative approach: we considered all samples that share a given allele and determined if a motif was shared between all these samples. To decide which motifs are shared, we used the Binding motifs from NetMHCIIpan 19 were determined in the following way: 16'000 random human peptides (2'000 of each length between 12 and 19 amino acids) were inputted into NetMHCIIpan. For each allele, the peptides with a "%Rank" better than 5
were kept and ggseqlogo 28 was used to draw the motifs from the corresponding "Core" sequences returned by NetMHCIIpan.
Comparison to other motif deconvolution methods
We compared the motifs found by MoDec with those predicted by Gibbscluster (version 2.0 17 ) and MEME version 4.12 20 (Suppl. Fig. 4) . For a comparison of the timing, the tools were launched on a single 3.3 GHz CPU with 2 GB of RAM, searching for 1 to 8 motifs in various samples.
Gibbscluster was run with the recommended parameters for HLA-II (5 seeds for the initial conditions, an initial MC temperature of 1.5, using a trash cluster with a threshold of 2 for this cluster, the rest being left unchanged). Gibbscluster suggests using a Kullback-Leibler criterion to select the optimal number of clusters from their deconvolution. In some cases, manual curation allowed to find additional clusters that had similarity with known HLA-II motifs, and we show the results of Gibbscluster including these additional clusters in Suppl. Figure 4 . MEME was run setting a motif width of 9, a maximum dataset size of 10'000'000 (needed due to the size of the samples) and the rest was left at default.
Investigation of properties of HLA-II ligands other than binding specificity
Analysis of N-and C-terminal flanking motifs was done with MoDec by taking the three amino acids upstream and downstream of the N-/C-terminus of the peptides that could be assigned to alleles (i.e., the peptides were extended based on their protein of origin to include the three amino acids upstream of N-terminus and downstream of C-terminus).
The peptide length distributions, binding core offset distributions and frequencies of proline two residues downstream of the N-terminus and upstream of the C-terminus, were computed for all peptides associated to each allele.
Binding affinity assays
Peptide binding affinity (Suppl. 
MixMHC2pred -a predictor of HLA-II ligands
We trained a predictor of HLA-II ligands (MixMHC2pred) using all our HLA-II peptidomics data (including the pan-HLA-II, HLA-DR and HLA-DR depleted peptidomics data). For a given allele, a, and peptide, n, the binding score is given by:
where ws represents the global binding core offset preference (computed combining all peptides associated to an allele); ̅ , is the position probability matrix for allele a (computed from all peptides associated to this allele with their respective binding core offset based on the highest responsibility value, and adding pseudocounts based on the BLOSUM62 substitution matrix with a parameter β=200 29 ); ̅ , and ̅ , are similar matrices representing the N-and C-terminal motifs (Suppl. Fig. 5a-b ; including here only the amino acids within the peptides); w N k and w C k represent the relative contributions of the N-/C-terminal motifs (i.e. the fraction of peptides assigned to each of these motifs).
See Equation (1) for the definition of other terms.
This binding score is then transformed to a percentile rank per peptide length by comparing it to the score of 10'000 random human peptides of the same length, and then further transformed to a global percentile rank by making that the top 1% random human peptides follow the same peptide length distribution than the global peptide length distribution observed in our HLA-II peptidomics data. Finally, when the score among multiple alleles is requested, the score from each peptide is taken as its best percentile rank among all the alleles.
Benchmarking HLA-II ligand predictions
The accuracy of MixMHC2pred was tested in multiple independent HLA-II peptidomics datasets 2, 8, [30] [31] [32] [33] [34] (Suppl. Table 2 ). The positives were the peptides of length 12-19 amino acids observed in these samples (removing all the peptides that were also part of the training data from MixMHC2pred for any of the alleles from a given sample). In each sample, we then added 4 times more negatives by randomly sampling human peptides of length 12-19 amino acids.
Predictions with MixMHC2pred and its different variants (see Fig. 2a ) were compared with those from NetMHCIIpan (version 3.2 19 with default parameters) based on the HLA-II typing provided in these studies (Suppl. Table 2 ). The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was computed for each sample separately ( Fig. 2a and Suppl. Fig. 7 ).
Benchmarking predictions of epitopes from tetramer assays
All the multimer/tetramer assay data for human CD4+ T cells from the IEDB database 18 were downloaded (as of 20.07.2018). We then filtered this data to remove peptides with non-standard amino acids and to keep peptides of length 12 and longer that were associated to a known allele based on the "Allele evidence codes": "MHC binding assay" or "T cell assay -Single MHC type present". Only interactions involving alleles available in MixMHC2pred were considered.
Predictions with MixMHC2pred and NetMHCIIpan version 3.2 19 were performed for each peptide with its associated HLA-II allele, both for the positive (1'319 peptides) and the negative (1'040 peptides) cases. The corresponding ROC curve and its AUC are showed in Fig. 2b .
Selection of candidate viral, bacterial and tumor-associated epitopes
To further benchmark MixMHC2pred, we retrieved a list of known viral, bacterial and melanoma-associated proteins (Suppl . Table 3a) 
Peptide synthesis
Peptides were synthesized at the Protein and Peptide Chemistry Facility, University of Lausanne, Switzerland, by standard solid phase chemistry on a multiple peptide synthesiser (Applied Biosystem). All peptides were >90% pure as indicated by analytic HPLC. Lyophilised peptides were diluted in pure DMSO at 10 mg/ml and aliquots at 1 mg/ml in 10% DMSO were prepared and stored at -80°C.
In vitro peptide stimulation
Peripheral and Ionomycine (Sigma-Aldrich, Missouri, USA) at 50ng/ml and 500ng/ml, respectively.
The following day, cells were collected and stained using anti-CD3-APC (clone UCHT1, and evaluated individually. In a similar procedure that was used to evaluate multiple peptides in a matrix format, individual selected peptides were added to newly seeded CD4+ T cells and after an overnight incubation the cells were evaluated for their expression of IFNγ and TNFα using the same method as described above (Suppl. Fig. 8 ef).
Patient and neoantigen description
Patient CTE-0007 is a patient with recurrent ovarian cancer. Clinical data and all methodologies for the identification of non-synonymous somatic mutations were already described 35 .
Identification and validation of neo-epitope specific CD4 + TILs
Neoantigen (mutation D246N in SGOL1)-specific CD4 + TILs were identified in patient CTE-0007 upon co-culture with tandem minigene-transfected autologous B cells. TILs were derived from tumor single cell suspensions and expanded with high-dose IL-2 (Proleukin, 6'000 IU/mL) for 15 days as previously reported 35 . In parallel, CD19 + cells were isolated from PBMCs using magnetic beads (Miltenyi) and expanded for 14 days 
